Paper37745839
Role of immunotherapy in chondrosarcoma: A case report and review of the literature.
Cohen-Nowak AJ and 7 others. Ther Adv Med Oncol, 2023. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Role of immunotherapy in chondrosarcoma: A case report and review of the literature. Papers, record 37745839. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37745839
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28241093 | Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. | Cancer | 2017 | https://conductscience.org/library/papers/28241093 | PubMed |
| 2 | 32344648 | Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma. | Cells | 2020 | https://conductscience.org/library/papers/32344648 | PubMed |
| 3 | 33203665 | Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/33203665 | PubMed |
| 4 | 31956474 | The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target. | J Bone Oncol | 2020 | https://conductscience.org/library/papers/31956474 | PubMed |
| 5 | 31498474 | Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis. | J Orthop Res | 2020 | https://conductscience.org/library/papers/31498474 | PubMed |
| 6 | 28878676 | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/28878676 | PubMed |
| 7 | 32612154 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. | Cell Mol Immunol | 2020 | https://conductscience.org/library/papers/32612154 | PubMed |
| 8 | 30253794 | Response to PD1 inhibition in conventional chondrosarcoma. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/30253794 | PubMed |
| 9 | 29862874 | Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma. | Int J Biol Markers | 2018 | https://conductscience.org/library/papers/29862874 | PubMed |
| 10 | 32910151 | Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32910151 | PubMed |
| 11 | 30519452 | Chondrosarcoma: biology, genetics, and epigenetics. | F1000Res | 2018 | https://conductscience.org/library/papers/30519452 | PubMed |
| 12 | 31578273 | Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. | Oncologist | 2020 | https://conductscience.org/library/papers/31578273 | PubMed |
| 13 | 17545802 | Update on chondrosarcomas. | Curr Opin Oncol | 2007 | https://conductscience.org/library/papers/17545802 | PubMed |
| 14 | 28688724 | PD-1 and PD-L1 expression in bone and soft tissue sarcomas. | Pathology | 2017 | https://conductscience.org/library/papers/28688724 | PubMed |
| 15 | 31629410 | Tumor-associated macrophages: an accomplice in solid tumor progression. | J Biomed Sci | 2019 | https://conductscience.org/library/papers/31629410 | PubMed |
| 16 | 36110930 | Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36110930 | PubMed |
| 17 | 27696380 | Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. | Cancer | 2017 | https://conductscience.org/library/papers/27696380 | PubMed |
| 18 | 25949923 | The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ. | Oncoimmunology | 2015 | https://conductscience.org/library/papers/25949923 | PubMed |
| 19 | 24897071 | Vascular pattern in enchondroma and chondrosarcoma: clinical and immunohistologic study. | Appl Immunohistochem Mol Morphol | 2014 | https://conductscience.org/library/papers/24897071 | PubMed |
| 20 | 8608988 | Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. | Int J Cancer | 1996 | https://conductscience.org/library/papers/8608988 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41752158 | Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41752158 | PubMed |
| 41609192 | A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi-Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De-Differentiated Chondrosarcoma. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/41609192 | PubMed |
| 41079102 | Andrographolide suppresses chondrosarcoma cell migration and invasion by inhibiting the PI3K/Akt/mTOR signaling pathway and activating autophagy. | Front Oncol | 2025 | https://conductscience.org/library/papers/41079102 | PubMed |
| 40927310 | Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment. | J Immunother Precis Oncol | 2025 | https://conductscience.org/library/papers/40927310 | PubMed |
| 40117529 | Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/40117529 | PubMed |
| 40004005 | Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40004005 | PubMed |
| 39652252 | Advancing Systemic Therapy in Chondrosarcoma: New Horizons. | Oncol Ther | 2025 | https://conductscience.org/library/papers/39652252 | PubMed |
| 39590345 | Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39590345 | PubMed |
| 39540661 | Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. | Cancer | 2025 | https://conductscience.org/library/papers/39540661 | PubMed |
| 39276177 | Comparisons of clinical characteristics, treatments, and outcomes among different pathological subtypes of chondrosarcoma in the spine. | J Neurooncol | 2024 | https://conductscience.org/library/papers/39276177 | PubMed |
| 39156101 | Global research development of chondrosarcoma from 2003 to 2022: a bibliometric analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39156101 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37745839
GET https://conductscience.org/api/papers/v1/37745839/references?page=2